MARKETSSTORY 01· JULY 17, 2026

Investors in ADMA Biologics reminded of class action deadlines

NDNewsDialy Desk1 MIN READ

Investors who took losses on a Nasdaq-listed stock are being reminded that legal deadlines in an active case are approaching. A class action, a lawsuit that lets a group of plaintiffs with similar claims pursue them together in one proceeding, has been filed against ADMA Biologics, Inc. (Nasdaq: ADMA). New York firm Pomerantz LLP announced the filing on July 16, 2026.

The suit against ADMA Biologics

Pomerantz LLP filed the class action against ADMA Biologics on behalf of investors who say they suffered losses on the stock. The firm's announcement did not specify what conduct is alleged or what damages are being sought.

Deadlines and contact information

Pomerantz describes the case as having upcoming deadlines. Shareholders who believe they qualify can reach Danielle Peyton at the firm by email at [email protected] or by phone at 646-581-9980.

NEXT STORY 02 →GPGI, Inc. investors face a class action deadline as Pomerantz LLP files suit

Keep reading

More from the desk.

02MARKETS

GPGI, Inc. investors face a class action deadline as Pomerantz LLP files suit

Investors who lost money on shares of GPGI, Inc. are being told time is running out to join a class action lawsuit filed against the company. A class action is a single proceeding that bundles many individual investor claims together, which

markets1 MIN

03MARKETS

MSA Safety schedules second quarter 2026 earnings conference call

A quarterly earnings call is a live session where company executives present recent financial results and take questions from Wall Street analysts and investors. MSA Safety Incorporated (NYSE: MSA) announced on July 16, 2026, that it will h

markets2 MIN

04MARKETS

BNY prices $500 million preferred stock offering via depositary shares

Half a billion dollars of new bank capital went to market on July 16, 2026, when The Bank of New York Mellon Corporation priced a public offering of depositary shares. A depositary share is a tradeable certificate that gives its holder a fr

markets2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk

Key takeaways

A securities class action lawsuit has been filed against ADMA Biologics, Inc. (Nasdaq: ADMA) on behalf of investors who say they suffered losses on the stock.
New York law firm Pomerantz LLP announced the filing on July 16, 2026.
Pomerantz describes the case as having upcoming deadlines that investors should be aware of.
The firm's announcement did not specify what conduct is alleged or what damages are being sought.
Shareholders who believe they qualify can contact Danielle Peyton at Pomerantz LLP by email at [email protected] or by phone at 646-581-9980.

Frequently asked

Which company is the class action filed against?

The class action was filed against ADMA Biologics, Inc., which trades on the Nasdaq under the ticker ADMA.

Who filed the lawsuit and when was it announced?

New York firm Pomerantz LLP filed the class action and announced the filing on July 16, 2026.

How can affected shareholders get more information or take part?

Shareholders who believe they qualify can reach Danielle Peyton at Pomerantz LLP by email at [email protected] or by phone at 646-581-9980.

What specific wrongdoing is alleged in the lawsuit?

The firm's announcement did not specify what conduct is alleged or what damages are being sought.

What is a class action?

A class action is a lawsuit that lets a group of plaintiffs with similar claims pursue them together in one proceeding.